Topical Itraconazole in Treating Patients With Basal Cell Cancer

Inclusion Criteria:

   - The subject must sign and date all informed consent statements; children will sign the
   assent form and their guardian will sign the consent form

   - The subject must be willing to apply the medications twice daily for 1 month

   - The subjects must have at least four BCCs in non-cosmetically sensitive sites

   - For women of child-bearing potential, a negative urine pregnancy test

   - Women of child-bearing potential are expected to use an effective method of birth
   control to prevent exposing a fetus to potentially dangerous agent with unknown risk

   - For male patients with female partners of childbearing potential, agreement to use
   adequate contraception while you are participating in the study and 1 month after
   applying your last dose

Exclusion Criteria:

   - Pregnancy or breast-feeding

   - History of congestive heart failure or other findings of ventricular dysfunction

   - History of current evidence of malabsorption or liver disease

   - Current immunosuppression or taking immunosuppressive drugs

   - Taking oral itraconazole

   - Taking any medication known to affect hedgehog (HH) signaling pathway

   - The subject has used topical or systemic therapies that might interfere with the
   evaluation of the study medication during the study; specifically these include the
   topical use to the study tumors of: glucocorticoids (ii) retinoids (e.g., etretinate,
   isotretinoin, tazarotene, tretinoin, adapalene) systemically or topically (iii)
   alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to more than 5% of the skin
   during the six months prior to study entry (iv) 5-fluorouracil or imiquimod; also -
   treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling
   within 60 days to starting study medication